🇺🇸 FDA

Company profile · Sponsor

Allogene

Allogene Therapeutics

ALLO · NYSE biotech SOUTH SAN FRANCISCO, CA, USA
Pipeline
8
Drugs
0
Patents
8

Quick answer

Allogene (ALLO) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker ALLO
Exchange NYSE
Company type biotech
Headquarters SOUTH SAN FRANCISCO, CA, USA
SEC CIK 0001737287

Pipeline (8)

Search pipeline →

  1. ALLO-501A

    Allogene

    Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

    phase 2 gene therapy active

    1 trial

  2. ALLO-605

    Allogene

    Relapsed/Refractory Multiple Myeloma

    phase 2 gene therapy terminated

    1 trial

  3. ALLO-647

    Allogene

    Relapsed/Refractory Large B Cell Lymphoma

    phase 2 mab terminated

    1 trial

  4. cemacabtagene ansegedleucel

    Allogene

    Large B-cell Lymphoma

    phase 2 gene therapy active

    1 trial

  5. ALLO-316

    Allogene

    Advanced/Metastatic Clear Cell Renal Cell Carcinoma

    phase 1 gene therapy active

    1 trial

  6. ALLO-329

    Allogene

    Systemic Lupus Erythematosus (With and Without Nephritis)

    phase 1 gene therapy active

    1 trial

  7. ALLO-501

    Allogene

    Relapsed/Refractory Large B Cell Lymphoma

    phase 1 gene therapy completed

    1 trial

  8. ALLO-715

    Allogene

    Relapsed/Refractory Multiple Myeloma

    phase 1 gene therapy completed

    1 trial

Patents (8)

Search patents →

  1. US 12404315

    Protease-activating CD45-gate CAR

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12365873

    Methods for transducing immune cells

    Expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12295362

    Formulations and processes for CAR T cell drug products

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12221462

    Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12215347

    Chimeric antigen receptors with enhanced signaling and activities and uses thereof

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12163153

    Methods of manufacturing allogeneic CAR T cells

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12163169

    Inducible chimeric cytokine receptors

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12104188

    Modified caspase-9 polypeptides and methods of use thereof

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Allogene?

Allogene (ALLO) is a biotech company. headquartered in SOUTH SAN FRANCISCO, CA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Allogene sponsor?

We track 8 ClinicalTrials.gov-linked programs for Allogene, including ALLO-501A and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Allogene company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.